Cagrilintide

REDEFINE 1

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Garvey WT et al. · The New England journal of medicine · 2025

Population: Adults with overweight and a coexisting condition, or obesity

The Phase 3 trial of cagrilintide coadministered with semaglutide, with relative change in body weight and the proportion reaching a 5% reduction at week 68 as coprimary endpoints.

Route reported

Subcutaneous

Schedule

Once weekly under the trial protocol

Duration

68 weeks

Context: Studies the combination, not cagrilintide alone. Findings belong to the coadministered regimen described by the authors.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Lau DCW et al. · Lancet (London, England) · 2021

Population: People with overweight or obesity, without diabetes

The dose-finding study of cagrilintide as monotherapy, comparing several doses against both placebo and liraglutide 3.0 mg over 26 weeks.

Route reported

Subcutaneous

Schedule

Once weekly under the trial protocol

Duration

26 weeks

Treatment arms

0.3 mg · 0.6 mg · 1.2 mg · 2.4 mg · 4.5 mg · Liraglutide 3.0 mg · Placebo

Context: Phase 2 dose-finding, not a confirmatory efficacy trial.

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial

Yamauchi T et al. · The lancet. Diabetes & endocrinology · 2026

The study reportedThese findings support the efficacy and safety of cagrilintide-semaglutide for weight management in individuals from east Asia with overweight or obesity, with or without type 2 diabetes.

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Rosenstock J et al. · Lancet (London, England) · 2026

The study reportedCagrilintide-semaglutide at doses of 2·4 mg each and 1·0 mg each met the primary endpoint, with statistically significant and clinically relevant HbA1c reductions versus placebo when added to basal insulin-treated type 2 diabetes. These reductions were accompanied by robust bodyweight reduction and no additional risk of hypoglycaemia.

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

Buse JB et al. · The lancet. Diabetes & endocrinology · 2026

The study reportedCagrilintide-semaglutide (2·4 mg each) was superior to semaglutide 2·4 mg in reducing HbA1c in participants with type 2 diabetes receiving metformin with or without an SGLT2 inhibitor. The safety profile of cagrilintide-semaglutide was consistent with the GLP-1 receptor agonist class and previous safety data for cagrilintide.

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Loomba R et al. · The lancet. Gastroenterology & hepatology · 2026

The study reportedIn participants with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, the combination of zalfermin 30 mg plus semaglutide 2·4 mg did not significantly increase the proportion of participants who had an improvement in liver fibrosis and no worsening of metabolic dysfunction-associated steatohepatitis compared with placebo by week 52.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Davies MJ et al. · The New England journal of medicine · 2025

The study reportedOnce-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Frias JP et al. · Lancet (London, England) · 2023

The study reportedIn people with type 2 diabetes, treatment with CagriSema resulted in clinically relevant improvements in glycaemic control (including CGM parameters). The mean change in HbA1c with CagriSema was greater versus cagrilintide, but not versus semaglutide.

Development of Cagrilintide, a Long-Acting Amylin Analogue

Kruse T et al. · Journal of medicinal chemistry · 2021

Describes the design and molecular properties of cagrilintide as a long-acting amylin analogue, including the modifications intended to extend its duration of action.

Context: Chemistry and preclinical characterisation; not a clinical study.